Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORE: Cilengitide plus standard chemoradiotherapy in newly diagnosed glioblastoma with unmethylated MGMT
2008-004457-15Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2009
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cilengitide in glioblastoma (GBM) (2 arms), sponsored by Merck KGaA. Primary endpoint: Overall survival. Started Aug 2009; status: completed.
02
Drugs
cilengitide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-004457-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004457-15.